Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial.

Kamble S, Weinfurt KP, Schulman KA, Reed SD.

Med Decis Making. 2013 Feb;33(2):215-24. doi: 10.1177/0272989X12464824. Epub 2012 Nov 5.

PMID:
23128579
2.

Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States.

Kamble S, Schulman KA, Reed SD.

Value Health. 2012 Jul-Aug;15(5):632-8. doi: 10.1016/j.jval.2012.02.011. Epub 2012 May 23.

3.
4.

Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.

Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, Diem P, Fermon C, Wentholt IM, Hoekstra JB, DeVries JH.

Diabet Med. 2011 Oct;28(10):1158-67. doi: 10.1111/j.1464-5491.2011.03256.x.

PMID:
21294770
5.

Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.

Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ.

Pharmacoeconomics. 2007;25(10):881-97.

PMID:
17887808
6.

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes.

Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N.

Health Technol Assess. 2004 Oct;8(43):iii, 1-171. Review.

7.

Continuous glucose monitoring systems for type 1 diabetes mellitus.

Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008101. doi: 10.1002/14651858.CD008101.pub2. Review.

PMID:
22258980
8.

Crossing the technology divide: practical strategies for transitioning patients from multiple daily insulin injections to sensor-augmented pump therapy.

Rubin RR, Borgman SK, Sulik BT.

Diabetes Educ. 2011 Jan-Feb;37 Suppl 1:5S-18S; quiz 19S-20S. doi: 10.1177/0145721710391107. Epub 2011 Jan 7.

PMID:
21217102
9.
10.

Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial.

Rubin RR, Peyrot M; STAR 3 Study Group.

Diabetes Technol Ther. 2012 Feb;14(2):143-51. doi: 10.1089/dia.2011.0162. Epub 2011 Dec 1.

11.
13.

Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children.

Zucchini S, Scipione M, Balsamo C, Maltoni G, Rollo A, Molinari E, Mangoni L, Cicognani A.

Diabetes Technol Ther. 2011 Dec;13(12):1187-93. doi: 10.1089/dia.2011.0080. Epub 2011 Aug 19.

PMID:
21854193
14.

Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada.

St Charles ME, Sadri H, Minshall ME, Tunis SL.

Clin Ther. 2009 Mar;31(3):657-67. doi: 10.1016/j.clinthera.2009.03.013.

PMID:
19393856
15.

Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes.

Thrailkill KM, Moreau CS, Swearingen C, Rettiganti M, Edwards K, Morales AE, Kemp SF, Frindik JP, Fowlkes JL.

Diabetes Technol Ther. 2011 Oct;13(10):1023-30. doi: 10.1089/dia.2011.0085. Epub 2011 Jun 30.

PMID:
21718094
17.

Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study.

Slover RH, Welsh JB, Criego A, Weinzimer SA, Willi SM, Wood MA, Tamborlane WV.

Pediatr Diabetes. 2012 Feb;13(1):6-11. doi: 10.1111/j.1399-5448.2011.00793.x. Epub 2011 Jul 3.

PMID:
21722284
18.

Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial.

Perkins BA, Halpern EM, Orszag A, Weisman A, Houlden RL, Bergenstal RM, Joyce C.

Can J Diabetes. 2015 Feb;39(1):50-4. doi: 10.1016/j.jcjd.2014.03.003. Epub 2014 Aug 29.

PMID:
25175313
19.
20.

Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial.

Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, Lilos P, Dickerman Z, Phillip M.

Pediatrics. 2003 Sep;112(3 Pt 1):559-64.

PMID:
12949284

Supplemental Content

Support Center